Neurobiology and Treatment of Reading Disability in NF-1
Neurobiology and Treatment of Reading Disability in Neurofibromatosis Type 1 (NF-1)
Sponsor: National Institute of Neurological Disorders and Stroke (NINDS)
This NA trial investigates Neurofibromatosis Type 1 and Reading Disabilities and is currently completed. National Institute of Neurological Disorders and Stroke (NINDS) leads this study, which shows 14 recorded versions since 2006 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
14 versions recorded-
Aug 2025 — Present [monthly]
Completed NA
-
Sep 2024 — Aug 2025 [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Jun 2023 — Jul 2024 [monthly]
Completed NA
-
Jun 2022 — Jun 2023 [monthly]
Completed NA
▶ Show 9 earlier versions
-
Dec 2021 — Jun 2022 [monthly]
Completed NA
-
Sep 2021 — Dec 2021 [monthly]
Completed NA
-
Feb 2021 — Sep 2021 [monthly]
Completed NA
-
Jan 2021 — Feb 2021 [monthly]
Completed NA
-
Jul 2020 — Jan 2021 [monthly]
Completed NA
-
Dec 2018 — Jul 2020 [monthly]
Completed NA
-
Jun 2018 — Dec 2018 [monthly]
Completed NA
-
May 2017 — Jun 2018 [monthly]
Completed NA
Status: Unknown Status → Completed
-
Jan 2017 — May 2017 [monthly]
Unknown Status NA
First recorded
Feb 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- National Institute of Neurological Disorders and Stroke (NINDS)
- Vanderbilt University
For direct contact, visit the study record on ClinicalTrials.gov .